Managing Erectile Dysfunction in Prostate Cancer

Addressing the physical and psychological toll of prostate cancer treatment requires a proactive approach to survivorship.

During the OneOncology APP Symposium, Dan Silver, PA-C, a physician assistant with Arizona Urology Specialists, emphasized the necessity of integrating sexual health management into the early stages of oncologic care.

Silver specializes in men’s health, including erectile dysfunction (ED), Peyronie’s disease, and hypogonadism.

The impact of prostate cancer modalities on sexual health

Silver noted that the mechanism of sexual dysfunction varies significantly depending on the chosen treatment. For patients undergoing androgen deprivation therapy (ADT), the primary driver is the suppression of testosterone, which directly compromises erectile function.

In the surgical setting, Silver explained that while many surgeons now employ nerve-sparing techniques during a prostatectomy, the nerves responsible for erections are frequently "stunned" during the procedure. He cautioned that clinicians must manage patient expectations regarding the timeline for recovery, as it can take up to two years for these nerves to regain function and for natural erections to return.

Radiation therapy presents a different clinical trajectory. Unlike the immediate impact of surgery, radiation-induced ED tends to be a gradual process, developing more slowly over time.

Protocols for penile rehabilitation

Silver emphasized the importance of early intervention. "The more that we do upfront, the better off people are going to be," Silver stated. To mitigate long-term damage and support penile rehabilitation, he utilizes a tiered treatment algorithm tailored to the patient’s specific therapy:

• Post-Prostatectomy Care: Silver typically initiates a regimen of daily Cialis (tadalafil). While the efficacy of oral medications can be variable in the early post-operative period, they serve as a foundational step in the rehabilitation process.
• ADT and Non-Responders: In patients receiving ADT, oral PDE5 inhibitors often prove ineffective due to the lack of circulating testosterone. In these cases, Silver moves quickly to alternative interventions, including vacuum pumps or injection therapy.

An individualized approach to survivorship

Silver, who joined Arizona Urology Specialists in 2016 after a diverse career in cardiology, intensive care, and internal medicine, stressed that treatment must be highly individualized. He reviews each patient’s comprehensive medical history to determine the most appropriate point to escalate from oral medications to mechanical or injectable options.

For oncology nurses and advanced practice providers, Silver’s insights underscore the need for early and open dialogue regarding sexual health. By addressing these concerns up front, providers can help patients navigate the complexities of recovery and maintain a higher quality of life throughout their survivorship journey.